Serina Therapeutics (NYSE: SER) on Thursday received an NYSE notice that it does not meet certain continued listing requirements under Sections 1003(a)(i) and (ii).
The company reported stockholders’ equity of $1.6M as of Sept. 30, 2025, and has recorded losses in three of the past four fiscal years ended Dec. 31, 2024.
The company must file a plan by Feb. 8, 2026, detailing how it will meet NYSE listing requirements by July 9, 2027, following a notice of non-compliance.
